Press Releases There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate ...

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate ...

My Hero Academia final season offers the perfect chance to revise Dabi’s fate and provide him with a more fitting anime-original ending.

SiTime Corporation completed a public offering of 2,012,500 shares, raising approximately $387.4 million at $200 per share.